Avian Fujian H5N1. Cell-based technology also has the potential for a faster start-up of the flu vaccine manufacturing process. By the time a vaccine was developed, tested, produced, and distributed, many individuals had already been infected. Preventive Medicine. The HAs of an influenza virus are antigens.
Solutions to limitations in current [ when? Of those, about 7, end up at the laboratory run by microbiologist John Barnes, who leads the CDC’s influenza genomics team. In the meantime, the flu virus continues to change, evolving in ways both expected and unforeseen. The first neutralizing antibodies were identified in , via experimentation;  with time researchers understood that the flu neutralizing antibodies were binding to the stalk of the Hemagglutinin protein ; later researchers identified antibodies that could bind to the head of those proteins. Later, some doses went unused.
Sign In See Subscription Options. Retrieved December 25, Archived from the original on June 27, This production process is the fastest because it is not limited by the selection of vaccine viruses that are adapted for growth in eggs or the development of cell-based vaccine viruses. Medicine Baltimore. Selecting Viruses for the Seasonal Influenza Vaccine. September 24, At this point, the viruses have been weakened or killed and the viral antigen is purified and placed inside vials, syringes, or nasal sprayers.